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A B S T R A C T
Objectives: We aimed to determine the incidence and relative risk (RR) of invasive pneumococcal disease
(IPD) in patients with asplenia/hyposplenism, using a nationwide population-based database.
Methods: From 2009 to 2018, all claimed cases of newly diagnosed asplenia/hyposplenism in the National
Health Insurance Service in South Korea were included. The incidence and RR of IPD in asplenia/
hyposplenism patients were investigated using the Korean Center for Disease Control criteria.
Results: Fifty-seven IPD cases were identified among 21,376 patients with 82,748 person-years of
exposure. The cumulative 8-year IPD incidence was 0.5%; 45.6% of the infections occurred within two
years after an asplenia/hyposplenism diagnosis. The age-standardised incidence rate was 104.5 per
100,000 person-years (95% confidence interval [CI],103.6–105.4). Patients aged <5 years had a 15.1-times
higher risk of IPD than those aged 60 years (95% CI: 5.8–39.5, p < 0.0001). The RR of IPD was 32.0 times
higher in patients with asplenia/hyposplenism than in the general population (95% CI, 21.7–47.0); the
standardized incidence ratio was 17.9(95% CI, 11.8–26.0).
Conclusions: This large population-based study highlights the high IPD incidence rate and RR in Korean
patients with asplenia/hyposplenism. Increased awareness and effective prevention strategies are
needed for these high-risk populations, especially children aged <5 years.
© 2020 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
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Asplenia, the absence of the spleen, is typically a result of
splenectomy and is rarely congenital. Hyposplenism is a disorder in
which the spleen's function and size are reduced due to several
underlying diseases (Di Sabatino et al., 2011). As various immune
cells and elements in the spleen, including heterogeneous splenic
macrophages, opsonins, IgM, and memory B cells, contribute to the* Corresponding author at: Department of Pediatrics, Severance Children's
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immune response, asplenia/hyposplenism can cause serious
bloodstream infections, especially infections caused by encapsu-
lated pathogens, including Streptococcus pneumoniae, Neisseria
meningitidis, and Haemophilus influenzae (Borges da Silva et al.,
2015; Rubin and Schaffner, 2014).
Numerous studies of such infections, especially invasive
pneumococcal disease (IPD) after splenectomy, have been pub-
lished (Krauth et al., 2008; King and Shumacker, 1952; Theilacker
et al., 2016). A systematic review reported an IPD incidence of 2.9%
in patients with severe post-splenectomy infections, while another
review reported 890 IPD cases per 100,000 person-years of severe
post-splenectomy infection among 21,404 person-years of expo-
sure (Cullingford et al., 1991; Holdsworth et al., 1991). However,
those studies were conducted before the 1990s and may not reflect
the current situation after the introduction of the pneumococcalciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
 of Medicine from ClinicalKey.com by Elsevier on November 18, 2020.
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congenital asplenia or hyposplenism, on the development of IPD,
compared with splenectomy, is unclear (William et al., 2007).
This study aimed to investigate the incidence of IPD among
patients with asplenia/hyposplenism and to determine the relative
risk (RR) of IPD in the PCV era, using a nationwide population-
based database. We also evaluated the risk factors for IPD and the
occurrence of invasive N. meningitidis and H. influenzae infections
in these high-risk populations.
Methods
Health Insurance Review and Assessment (HIRA) service database
South Korea has a universal health coverage system, the
National Health Insurance Service (K-NHIS), which covers approx-
imately 98% of the overall Korean population (51,420,000 citizens
in the 2017 census) (Kim et al., 2014). The HIRA assesses the claims
from almost 80,000 medical institutions included in the K-NHIS
and has an extensive database that contains detailed information
about the diagnoses, treatment, surgical history, and prescription
drugs of patients from the entire population.
The National Infectious Disease Surveillance System in Korea
The Korean Center for Disease Control (KCDC) operates the
National Infectious Disease Surveillance System and provides real-
time information on the occurrence of mandatory notifiable
infectious diseases through an Infectious Disease Portal (http://
www.cdc.go.kr/npt/biz/npp/nppMain.do). The KCDC publishes the
Infectious Disease Surveillance Yearbook annually with various
statistics on infectious diseases, and data on the age distribution of
the general population (KCDC, 2017). S. pneumoniae (since
September 2014), H. influenzae type B (since September 2013),
and N. meningitidis (since 2001) infections are mandatorily
notifiable diseases; clinicians or medical institutions that diagnose
or detect these infections are obligated by law to report all such
cases. Also, the National Immunisation Program (NIP) provides free
of charge vaccination against those pathogens for the pediatric
population. From 2015 to 2018, the complete vaccination rate
included in the NIP (except N. meningitidis) is 94–97% for 1-year
olds and 92–95% for 2-year olds in Korea.
Study population
All claimed cases of asplenia/hyposplenism in South Korea from
1 January 2008 to 31 December 2018 were included. Patients withFigure 1. Flowchart for inclusio
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cation of Disease (KCD) codes adapted from the International
Classification of Diseases 10th revision (ICD-10). Patients with
asplenia/hyposplenism were defined as those diagnosed with
congenital asplenia (Q89.00)/hyposplenism (D73.0) or those who
underwent a splenectomy (procedure codes: P2091–P2093). As
previous cases may confound the actual incidence, the claims data
for 2008 were excluded, to account for a wash-out period.
Definitions
To analyze the incidence and risk factors of IPD in asplenia/
hyposplenism patients, all codes defining IPD among the KCD
codes were included [Method 1]. IPD was defined using the KCD
codes, namely, A40.3 (pneumococcal sepsis), G00.1 (pneumococcal
meningitis), K67.8 (pneumococcal peritonitis), J13 (pneumococcal
pneumonia), A49.1 (pneumococcal infection), I30.1 (pneumococcal
endocarditis), M00.1 (pneumococcal arthritis), and B95.3 (pneu-
mococcal infections in other sites), with at least one of the
following diagnostic codes: K65.0 (acute peritonitis), M00.8
(arthritis and polyarthritis due to other specified bacterial agents),
O85 (puerperal sepsis), P23.6 (congenital pneumonia due to other
bacterial agents), and/or I33.0 (acute and subacute infective
endocarditis). To compare the incidence rate of IPD between the
patients with asplenia/hyposplenism and the general population,
we used the IPD criteria of the KCDC to unify the case definition
[Method 2]. The KCDC criteria use only the K65 and B95.3 codes for
pneumococcal peritonitis (except the K67.8 code) and exclude the
A49.1 code for non-specific pneumococcal infection. In case of
other invasive infections due to encapsulated bacteria, invasive N.
meningitidis infection was defined using the A39.0–39.9 codes, and
invasive H. influenzae infection was defined using the A41.3, A49.2,
G00.0, J14, J20.1, G00.0, and B96.3 codes.
Comorbidity was defined as a disease whose code was
registered or persisted between one year prior to the index date
(date when the first asplenia-related code was inserted) and 30
days after the index date. We used the Charlson Comorbidity Index
with modifications to categorize the comorbidities (Quan et al.,
2005). We selected Hodgkin’s disease, portal hypertension,
idiopathic thrombocytopenic purpura, thalassemia, hereditary
spherocytosis, autoimmune lymphoproliferative syndrome, post-
transplant lymphoproliferative disease, and primary immunodefi-
ciency diseases, including hemophagocytic lymphohistiocytosis,
as the known risk factors for severe post-splenectomy infection
(Bisharat et al., 2001; Sinwar, 2014). Antimicrobial prophylaxis was
defined as administering oral antimicrobials for at least nine
months within one year of the index date. IPD-related deaths weren of the study population.
edicine from ClinicalKey.com by Elsevier on November 18, 2020.
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during intravenous antimicrobial treatment due to IPD.
Statistical analysis
Continuous variables were expressed as the mean  standard
deviation and were compared using the independent t-test.
Categorical variables were expressed as number (%) and were
compared using the chi-square test or Fisher’s exact test. Cox
proportional hazards regression analysis was performed to
identify the factors associated with infection risk after asplenia/
hyposplenism (sex, age at diagnosis/surgery, comorbidities, and
cause of asplenia/hyposplenism). The Kaplan-Meier method and
log-rank test were used to compare the cumulative incidence rates
of infection according to the cause of asplenia/hyposplenism. Age-
specific rates, age-standardized rates (ASRs), and standardized
incidence ratios (SIR) with 95% confidence intervals (CIs) were
calculated. Rates were expressed per 100,000 person-years. The
ASRs were calculated for different age groups (0–4, 5–19, 20–39,
40–59, and 60 years), and the SIR was used to compare the
incidence of infection between asplenia patients and the general
population. For comparison, we used the number of reported cases
of infectious diseases in the general population, as recorded in the
2017 Infectious Disease Surveillance Yearbook (KCDC, 2017). The
95% confidence intervals of SIR were calculated using a Poisson
distribution. All statistical tests were two-sided, and P values (p)
<0.05 were considered statistically significant. SAS Enterprise 9.4
software (SAS Institute, Cary, NC) was used for statistical analysis. RTable 1
Characteristics of the study population.
Number of patients Total N, N = 21,376 (%
Age at diagnosis of congenital asplenia/splenectomy,
mean years, SD
56.02  16.90 
0 to 4 years 123 0.5
5 to 19 years 712 3.3
20 to 39 years 2481 11.
40 to 59 years 7922 37




Mean duration of follow-up, years, SD 3.87  2.97 
Causes of asplenia
Splenectomy 20,524 96
Congenital asplenia/hyposplenism 852 3.9
Comorbiditiesa
Any comorbidities 20,544 96
Cardiovascular disease 10,889 50
Neurological disease 1225 5.7
Endocrine disease 9787 45
Liver disease 9111 42
Respiratory disease 8773 41
Renal disease 656 3.0
Malignancy or immunosuppression 14,381 67
Gastrointestinal disease 8925 41
Rheumatic disease 1022 4.7
Others 9263 43
Risk factors for severe post-splenectomy infection 1964 9.1
Hodgkin disease 12 0.0
Portal hypertension 27 0.1
Idiopathic thrombocytopenic purpura 1581 7.4
Thalassemia 3 0.0
Hereditary spherocytosis 330 1.5
Autoimmune lymphoproliferative syndrome 13 0.0
Post-transplant lymphoproliferative disease 4 0.0
Primary immunodeficiency 18 0.0
Antimicrobial prophylaxisa 191 0.8
SD, standard deviation.
a Antimicrobial prophylaxis was defined as oral antimicrobials prescribed for at least ni
code was inserted).
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Ethical statement
Since we extracted the patients’ information after de-identifi-
cation, the patient’s informed consent was waived, and institu-
tional review board approval was not required.
Results
The details of patient selection in this study are shown in Figure
1. From January 2008 to December 2018, 23,542 patients with
asplenia/hyposplenism were identified from the HIRA database.
After excluding 2105 patients based on the exclusion criteria,
21,376 (20,524 [96.0%] who underwent splenectomy and 852
[4.0%] diagnosed with congenital asplenia/hyposplenism) were
included. Among patients with congenital asplenia, 87 (10.2%, 87/
852) had the diagnostic codes for congenital heart diseases, and 13
of them (14.9%, 13/87) had a diagnostic code for right isomerism.
The male-to-female ratio was 52.5:47.5, and the average age at the
time of asplenia/hyposplenism (at the time of splenectomy or
diagnosis of congenital asplenia/hyposplenism) was 56.0 years
(16.9 years). The annual number of claimed cases for asplenia/
hyposplenism tended to increase slightly over the years, with a
non-significant trend (average annual percentage change = 0.4%;
p = 0.08). The mean follow-up duration was 3.9 years ( 3.0 years).) Non-infection,
N = 21,319
(%) Infection, N = 57 (%) P-value
56.04  16.88 50.56  22.40 0.07
8 118 0.55 5 8.77 <.0001
3 712 3.34 0 0.00
61 2471 11.59 10 17.54
.06 7905 37.08 17 29.82
.43 10,113 47.44 25 43.86
.46 11,179 52.44 35 61.40 0.17
.54 10,140 47.56 22 38.60
3.87  2.97 2.20  2.12 <.0001
.01 20,474 96.04 50 87.72 0.0073
9 845 3.96 7 12.28
.11 20,491 96.12 53 92.98 0.28
.94 10,857 50.93 32 56.14 0.43
3 1219 5.72 6 10.53 0.14
.78 9757 45.77 30 52.63 0.30
.62 9090 42.64 21 36.84 0.38
.04 8750 41.04 23 40.35 0.92
7 655 3.07 1 1.75 1.00
.28 14,346 67.29 35 61.4 0.34
.75 8902 41.76 23 40.35 0.83
8 1017 4.77 5 8.77 0.20
.33 9235 43.32 28 49.12 0.38
9 1959 9.19 5 8.77 0.91
6 12 0.06 0 0.00 >0.999
3 27 0.13 0 0.00 >0.999
0 1577 7.40 4 7.02 >0.999
1 3 0.01 0 0.00 >0.999
4 329 1.54 1 1.75 0.5885
6 13 0.06 0 0.00 >0.999
2 4 0.02 0 0.00 >0.999
8 18 0.08 0 0.00 >0.999
9 189 0.89 2 3.51 0.09
ne months during one year after the index date (date when the first asplenia-related
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one comorbidity, and the proportion of patients with any risk
factor for severe post-splenectomy infection was 9.2% (n = 1964);
only 0.9% (n = 191) received oral antimicrobial prophylaxis
(Table 1). The most commonly used oral antimicrobial agents
were cephalosporins (mostly cephalexin, cephradine, cefadroxil,
and cefuroxime), accounting for 44.5%, followed by quinolones,
25.2%; penicillin, 25.1%; and macrolides, 9.1%.
Incidence of IPD in asplenia/hyposplenism patients
Of 21,376 patients with asplenia/hyposplenism, 57 experienced
IPD in 82,748 person-years of exposure. Only one elderly patient
with IPD had a concurrent H. influenzae infection. The 1-, 5-, and 8-
year cumulative IPD incidence was 0.1%, 0.3%, and 0.5%,
respectively, after asplenia/hyposplenism (Figure 2A). Almost half
of the infections (45.6%, 26/57) developed within two years after
asplenia/hyposplenism, while 14.0% of the infections (8/57)
developed after more than five years (Figure 2B). By age group,
the 8-year cumulative IPD incidence in patients aged <5 years of
12.0% was significantly higher than that in the other age groups
(0.5%; p < 0.0001 by log-rank test; Figure 2C).Figure 2. Cumulative incidence of invasive pneumococcal disease (IPD) in patients wit
Cumulative incidence of IPD in patients with asplenia/hyposplenism according to age gro
criteria (D).
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years in all age groups (95% CI: 52.2–89.3), and the ASR was 104.5
per 100,000 person-years (95% CI: 103.6–105.4). After sex
standardization, the patients with asplenia aged 0–4 years had
the highest incidence rate of 748.8 per 100,000 person-years (95%
CI: 737.3–760.4; Figure 2D).
Characteristics of IPD in patients with asplenia/hyposplenism
Among the 57 IPD cases, IPD developed in the 50 (87.7%)
patients with splenectomy and in seven (12.3%) patients with
congenital asplenia/hyposplenism. There were six (10.5%, 6/57)
IPD-related mortalities. Non-specific pneumococcal infection
(A49.1) was the most common diagnosis (31.6%, 18 patients),
followed by pneumococcal pneumonia (J13), peritonitis (K67.8),
sepsis (A40.3), arthritis (M00.1), and infectious endocarditis
(I30.1), accounting for 31.6% (n = 18), 29.8% (n = 17), 21.1%
(n = 12), 8.8% (n = 5), 5.3% (n = 3), and 3.5% (n = 2) of the cases,
respectively. Among the 18 patients with ‘'non-specific pneumo-
coccal infections’, we additionally searched the other inserted
diagnostic codes to specify the infection site or organ. There were
seven cases of pneumonia (38.9%, 7/18), four cases of peritonitish asplenia/hyposplenism (A). Distribution of IPD after asplenia/hyposplenism (B).
ups (C). Sex standardized, age-specific rate of IPD according to the two different IPD
edicine from ClinicalKey.com by Elsevier on November 18, 2020.
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two cases of neutropenic fever (11.1%, 2/18), one case of bacteremia
(5.6%, 1/18), and one of osteomyelitis (5.6%, 1/18). For the
remaining one patient, it was difficult to estimate the site of
infection through additional diagnostic code searching.
Two patients with IPD were observed in the 0–4 years group.
One was diagnosed with congenital asplenia before his first
birthday and had IPD at the age of one. The other patient had a
splenectomy at the age of two years and had IPD at four years. Both
of these patients survived.
Risk factors for IPD
In the univariate analysis, young age (<5 years) and congenital
asplenia/hyposplenism diagnosis were significant risk factors for
IPD (Table 2). After adjusting for sex, comorbidities, risk factors for
severe post-splenectomy infections, and antimicrobial prophylax-
is, the IPD rate was still 13.8 times higher in patients aged <5 years
than in those aged 60 years (95% CI, 3.7–51.6; p < 0.0001);
however, no significant difference occurred for congenital asple-
nia/hyposplenism (adjusted hazard ratio = 1.7; 95% CI, 0.6–4.5;
p = 0.33; Table 2).
RR of IPD compared with that in the general population
Based on the Korean CDC case definition [Method 2], 18 non-
specific pneumococcal infections, and twelve pneumococcal
peritonitis cases were excluded from the analysis. Detailed age-
specific rates, according to the KCDC criteria, are shown in
Supplementary Table S1. According to the age group and KCDC
criteria, the crude IPD RR was 32.0 (32.6 vs. 1.02 per 100,000
person-years in the asplenia group and general population,
respectively; Table 3). After age standardization, the RR of IPD
was 17.9 times higher in the asplenia/hyposplenism group than in
the general population (SIR = 17.9; 95% CI, 11.8–26.0; Figure 3). In
particular, the SIR in the age groups of 5–19, 20–39, and <5 years
were 100-fold higher than the IPD incidence in the general
population (Figure 3).
Discussion
This population-based study shows the incidence of IPD in
patients with asplenia/hyposplenism in the PCV era. The incidenceTable 2
Risk factors for invasive pneumococcal infection in patients with splenectomy/asplenia
Variable 
Age at diagnosis/surgery 0 to 4 years 
　 5 to 19 years 
　 20 to 39 years 
　 40 to 59 years 





Risk factors for severe post-splenectomy infection No 
　 Yes 
Antimicrobial prophylaxisb No 
　 Yes 
Causes of asplenia Splenectomy 
　 Congenital asplenia/hyposple
CI, confidence interval; HR, hazard ratio.
a Univariate and multivariate Cox regression analyses were performed.
b Antimicrobial prophylaxis was defined as oral antimicrobials prescribed for at least n
code was inserted).
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crude analysis and 104.5 per 100,000 person-years after age
adjustment, which is comparable to that reported in previous
studies (36 to 3000 per 100,000 person-years, Table 3) (Aavitsland
et al., 1994; Arnott et al., 2018; Backhaus et al., 2016; Bisharat et al.,
2001; Choe et al., 2017; Cullingford et al., 1991; Eber et al., 1999;
Ejstrud et al., 2000; Foss Abrahamsen et al., 1997; Holdsworth
et al., 1991; Kyaw et al., 2006; Madenci et al., 2019; Marrie et al.,
2016). Our data also showed that the risk of IPD was 17.9 (age-
adjusted) to 32.0 (crude) times higher in the study population than
in the general population. Previous studies, since the 1990s, have
shown that the RR in asplenia patients ranges from 14.1 to 36.6
without age adjustment (Table 3) (Aavitsland et al., 1994; Arnott
et al., 2018; Backhaus et al., 2016; Bisharat et al., 2001; Choe et al.,
2017; Cullingford et al., 1991; Eber et al., 1999; Ejstrud et al., 2000;
Foss Abrahamsen et al., 1997; Holdsworth et al., 1991; Kyaw et al.,
2006; Madenci et al., 2019; Marrie et al., 2016). Our high RR implies
that improved awareness among patients and the development of
effective prevention strategies are still warranted, even in the PCV
era.
This epidemiological study has several strengths. First, our
study investigated the IPD incidence in more than 21,000 patients
with 82,000 person-years of exposure, minimizing the likelihood
of overestimation. In previous studies, the incidence of IPD varied
in each study, from 36 to 3000 per 100,000 persons-years. Several
possible reasons may be suggested for this difference, such as
different case definitions, ethnicity, regional diversity, and various
national vaccination programs. Also, the study population's size is
one of the most important factors in estimating the incidence of
IPD. The number of studies reporting a high incidence of IPD
(>1000 per 100,000) has not been large; most study populations
have been relatively small, with less than 1000 study participants
(Ejstrud et al., 2000; Madenci et al., 2019; Marrie et al., 2016).
Second, our data reflect the status of high pneumococcal
vaccination coverage in the general population. In Korea, the
PCV13/PCV10 vaccination for all young children has been included
in the National Immunisation Program (NIP) since 2014, and the
pneumococcal polysaccharide vaccine (PPSV23) for older adults
aged 65 years was introduced in 2013 (Heo et al., 2018). After
implementing the NIP, the coverage rate of PCV increased from 65%
in 2012 to 97% in 2017, and that of PPSV23 among older adults
increased from 5% in 2013 to 57% in 2014 (Heo et al., 2018). Thus, it
is likely that pneumococcal vaccinations were given as scheduled,.
Crude HRa Adjusted HRa
HR (95% CI) P-value HR (95% CI) P-value
15.10 (5.7839.46) <.0001 13.79 (3.6851.63) <.0001
0.73 (0.173.07) 0.66 0.71 (0.163.22) 0.66
1.06 (0.482.35) 0.89 1.06 (0.472.44) 0.88
0.78 (0.421.45) 0.43 0.79 (0.421.46) 0.44
1 (reference) 　 1 (reference) 　
1 (reference) 　 1 (reference) 　
0.70 (0.411.19) 0.19 0.73 (0.421.24) 0.24
1 (reference) 　 1 (reference) 　
0.67 (0.241.86) 0.45 0.92 (0.302.75) 0.87
1 (reference) 　 1 (reference) 　
0.80 (0.322.01) 0.64 0.90 (0.352.32) 0.82
1 (reference) 　 1 (reference) 　
3.45 (0.8414.13) 0.09 0.51 (0.092.85) 0.44
1 (reference) 　 1 (reference) 　
nism 3.13 (1.426.90) 0.005 1.66 (0.614.54) 0.33
ine months during one year after the index date (date when the first asplenia-related
 Medicine from ClinicalKey.com by Elsevier on November 18, 2020.
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Table 3
Summary of major studies on the incidence of severe infection in patients with asplenia/hyposplenism published since 1990.
Country, year
published
Study method Outcome General population Estimated
RR
Ref
Design Population at risk No of
population
Age Study period No of
cases





UK, 1991 Literature review Post-splenectomy 5902 Any 1952–1987 173 All severe infections
(B, M, PP)
N/Ab Holdsworth et al.
(1991)
Australia, 1991 Literature review Post-splenectomy 21,404 PYs Any 1981–1991 N/A All severe infections
(B, M, PP)
890 Cullingford et al.
(1991)






Any 2009–2018 27 IPDs 32.63 1.02 32.0 Our data
Korea, 2017 Single-center,
retrospective
Post-splenectomy 213  18 y 1997–2016 6 All severe infections 280d Choe et al. (2017)
Australia, 2018 Population-
based cohort




Arnott et al. (2018)
Australia, 1991 Population-
based cohort




Post-splenectomy 195  18 y 2005–2014 13 Sepsis requiring
hospitalization
1800 Madenci et al.
(2019)
Canada, 2016 Case-control Post-splenectomy 825 PYs Any 2000–2014 37 IPDs 3000 82 36.6 Marrie et al. (2016)
Sweden, 2016 Population-
based cohort




Post-splenectomy 1648 Any 1988–1999 30 All severe infections
(B, M)











330 Children 1989–1995 4 All severe infections
(B, M)





325 1568 1969–1980 10 IPDs (B, M) 226 11 20.5 Foss Abrahamsen
et al. (1997)
Norway, 1994 Case-control Post-splenectomy 3000 PYs N/A 1992–1993 8 IPDs (culture-
confirmed)
267 11 25.0 Aavitsland et al.
(1994)
B, bacteremia; IPD, invasive pneumococcal disease; M, meningitis; N/A not applicable; PP, pneumococcal pneumonia; PY, patient-years; RR, relative risk.
a Asplenia includes post-splenectomy.
b S. pneumoniae accounts for 56.7%, and H. influenzae accounts for 6.3% of cases.
c S. pneumoniae accounts for 66% of cases among 358 etiology-proven, invasive infections.
d 3 Pneumococcal bacteremia infections.
e 27 Invasive pneumococcal infections and one Neisseria meningitidis infection.
f S. pneumoniae infection accounts for 31.6% of cases (six cases).
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Figure 3. Standardized incidence ratios (SIR) of IPD in patients with asplenia/hyposplenism compared with that in the general population.
492 J.-M. Kang et al. / International Journal of Infectious Diseases 98 (2020) 486–493regardless of the asplenia status in young children or older adult
patients. PCV vaccination in young children can also change the
carriage strain of older populations from PCV serotypes to less
virulent, non-PCV serotypes, which may indirectly affect the
unvaccinated adult patients with asplenia/hyposplenism (Kim
et al., 2016; Rubin and Schaffner, 2014). However, we could not find
significant differences in the incidence of IPD among patients with
asplenia/hyposplenism before and after 2014, when PCV/PPSV23
was introduced in the NIP (89.5 and 77.0 per 100,000 person-years
before and after 2014, respectively, p = 0.59). A possible explana-
tion may be the presence of reporting bias. In Korea, since PCV was
included in the NIP in 2014, reporting of IPD became mandatory.
Therefore, there was a possibility of underreporting before 2014. To
clarify PCV's effects on this population, a long-term study,
including pneumococcal serotype analysis, is warranted.
The extremely low coverage rate (0.9%) of antimicrobial
prophylaxis in South Korea is one of our most unexpected findings.
We defined antimicrobial prophylaxis as the use of oral anti-
microbials for at least nine months within one year of the index
date; only 0.9% of the study population fit this criterion. For
reference, only 2.3% of patients are prescribed for 3–6 months, and
only 1.2% are prescribed for 6–9 months; therefore, it seems that
the oral antimicrobial prescription for prophylaxis itself has been
not well practiced in South Korea, regardless of the prescription
period after splenectomy or diagnosis of asplenia/hyposplenism.
We do not know the exact cause of this finding, but the lack of
awareness of the importance of antimicrobial prophylaxis and the
traditional medical habits of prescribing non-antimicrobial pro-
phylaxis among clinicians, including surgeons in South Korea
might be the possible causes. This finding reminds us that actual
clinical practice may be inconsistent with the guidelines. In this
case, establishing and managing a patient registry can have
practical advantages. Arnott et al. recently reported a decrease in
IPD incidence from 150 to 36 per 100,000 person-years among
3221 patients with asplenia/hyposplenism after enrolment in the
Spleen Registry in Australia. They emphasized the importance of aDownloaded for Anonymous User (n/a) at Yonsei University College of
For personal use only. No other uses without permissionlong-term, multi-disciplinary approach including education, clini-
cal guidance, including advice on antimicrobial prophylaxis and
emergency medicine, and a personalized vaccine report for
registrants and clinicians (Arnott et al., 2018). However, concerning
cost-effectiveness, the emergence of antimicrobial-resistant
pathogens and poor compliance, high-level evidence for these
recommendations are still lacking; therefore, further studies are
needed on the exact effect of each prevention strategy, such as
vaccination schedule or antimicrobial prophylaxis (Khasawneh
et al., 2019; Spijkerman et al., 2018).
Holdsworth et al. reported that the rate of post-splenectomy
infection in children aged <5 years was 10.4%, which was higher
than 0.9% of adults (Holdsworth et al., 1991). We confirmed that a
patient age <5 years is a significant risk factor for IPD in patients
with asplenia/hyposplenism. There was no difference in the
incidence rate between splenectomy-related and congenital
asplenia/hyposplenism after age adjustment in the multivariate
analysis. This finding, regardless of the cause of asplenia/
hyposplenism, emphasizes that the spleen's immunological role
is particularly important in younger children who still lack
immunological experience - both in terms of immunological
maturity and exposure to pathogens. Aranburu et al. reported that
memory B cells in infants were less mutated, resulting in reduced
affinity maturation, but became highly mutated at 6–7 years of age
in the presence of a germinal center and spleen (Aranburu et al.,
2017). They also reported that children with congenital asplenia
could not produce highly mutated IgM memory B cells, even later
in life. These findings imply that vaccination may be sub-optimally
effective for infants and young children with splenectomy or
congenital asplenia/hyposplenism compared to that for splenec-
tomized adult patients. When clinically determining the timing of
splenectomy, it is critical to consider delaying the surgery after five
years of age, and it is also necessary to induce a sufficient memory
immune response by completing PCV vaccination before surgery.
This study had some limitations. First, it was a retrospective
study; underreporting was possible. However, despite the possibility Medicine from ClinicalKey.com by Elsevier on November 18, 2020.
. Copyright ©2020. Elsevier Inc. All rights reserved.
J.-M. Kang et al. / International Journal of Infectious Diseases 98 (2020) 486–493 493of underestimation, the underreporting bias could be offset because
the same KCDC criteria [Method 2] were used when determining the
RRof IPD in the patient population compared with that in the general
population. Secondly, since the data on vaccination records and
pneumococcalserotypeswerenot availableintheHIRAdatabase, the
direct effects of IPD following pneumococcal vaccination and
serotype differences could not be assessed. Thirdly, the rate of
antimicrobial prophylaxis in patients with asplenia/hyposplenism
was extremely low in Korea (0.9%); thus, the sample size was
insufficient for assessing its effectiveness. Finally, the prevalence of
some high-risk factors, such as thalassemia and hereditary
spherocytosis, is very low among Korean people, making it difficult
to assess the additional IPD risk associated with these diseases.
Nevertheless, this is the largest population-based study to
provide information on the high IPD incidence in patients with
asplenia/hyposplenism in the PCV era. It is also the first study to
present the age-specific RR for IPD in high-risk patients compared
with that in the general population. Our data supported the notion
that young children had a higher incidence of IPD than other age
groups. Moreover, congenital asplenia/hyposplenism did not have
an additional risk of IPD compared to splenectomy, in the
multivariate analysis.
In conclusion, the incidence of IPD was high at 104.5 per
100,000 person-years in Korean patients with asplenia/hyposplen-
ism. This risk was more than 18 times higher than that in the
general population. Increased awareness regarding these high-risk
populations, especially children aged <5 years, is required, and
further studies are needed to assess the effectiveness of preventive
methods, including pneumococcal vaccination.
Contributions
Ji-Man Kang, Kyong Ihn, and Jong Gyun Ahn designed the study,
analyzed and interpreted the data, and wrote the manuscript. Eun
Hwa Kim and Minkyung Han collected, assembled, and analyzed
the data. Inkyung Jung analyzed and interpreted the data. All






This work was supported by the Basic Science Research Program
through the National Research Foundation of Korea (NRF) funded by
the Ministry of Education [grant number: 2019032869] and The
Ministry of Education commissioned to the NRF.
Appendix A. Supplementary data
Supplementary material related to this article can be found, in
the online version, at doi:https://doi.org/10.1016/j.ijid.2020.07.013.Downloaded for Anonymous User (n/a) at Yonsei University College of M
For personal use only. No other uses without permission. CReferences
Aavitsland P, et al. Risk of pneumococcal disease in individuals without a spleen.
Lancet 1994;344:1504.
Aranburu A, et al. Human B-cell memory is shaped by age- and tissue-specific T-
independent and GC-dependent events. Eur J Immunol 2017;47:327–44.
Arnott A, et al. A registry for patients with asplenia/hyposplenism reduces the risk
of infections with encapsulated organisms. Clin Infect Dis 2018;67:557–61.
Backhaus E, et al. Epidemiology of invasive pneumococcal infections: manifes-
tations, incidence and case fatality rate correlated to age, gender and risk
factors. BMC Infect Dis 2016;16:367.
Bisharat N, et al. Risk of infection and death among post-splenectomy patients. J
Infect 2001;43:182–6.
Borges da Silva H, et al. Splenic macrophage subsets and their function during
blood-borne infections. Front Immunol 2015;6:480.
Choe Y-J, Seo E, Lee J. A retrospective study of invasive bacterial infections in
children with asplenia. Pediatr Infect Vaccine 2017;24:160–7.
Cullingford GL, et al. Severe late postsplenectomy infection. Br J Surg 1991;78:716–
21.
Di Sabatino A, Carsetti R, Corazza GR. Post-splenectomy and hyposplenic states.
Lancet 2011;378:86–97.
Eber SW, et al. Frequency of very late fatal sepsis after splenectomy for hereditary
spherocytosis: impact of insufficient antibody response to pneumococcal
infection. Ann Hematol 1999;78:524–8.
Ejstrud P, et al. Risk and patterns of bacteraemia after splenectomy: a population-
based study. Scand J Infect Dis 2000;32:521–5.
Foss Abrahamsen A, et al. Systemic pneumococcal disease after staging splenecto-
my for Hodgkin’s disease 1969–1980 without pneumococcal vaccine protec-
tion: a follow-up study 1994. Eur J Haematol 1997;58:73–7.
Heo JY, et al. Incidence and case fatality rates of community-acquired pneumonia
and pneumococcal diseases among Korean adults: catchment population-based
analysis. PLoS One 2018;13:e0194598.
Holdsworth RJ, Irving AD, Cuschieri A. Postsplenectomy sepsis and its mortality
rate: actual versus perceived risks. Br J Surg 1991;78:1031–8.
(KCDC) Korea Centers for Disease Control and Prevention. The 2017 Infectious
Disease Surveillance Yearbook. 2017.
Khasawneh MA, et al. Outcomes after splenectomy in children: a 48-year
population-based study. Pediatr Surg Int 2019;35:575–82.
Kim L, Kim JA, Kim S. A guide for the utilization of Health Insurance Review and
Assessment Service National Patient Samples. Epidemiol Health 2014;36:
e2014008.
Kim YK, LaFon D, Nahm MH. Indirect effects of pneumococcal conjugate vaccines in
national immunization programs for children on adult pneumococcal disease.
Infect Chemother 2016;48:257–66.
King H, Shumacker [290_TD$DIFF][291_TD$DIFF]Jr. HB. Splenic studies. I. Suscep-
tibility to infection after splenectomy performed in infancy. Ann Surg
1952;136:239–42.
Krauth MT, et al. The postoperative splenic/portal vein thrombosis after
splenectomy and its prevention–an unresolved issue. Haematologica
2008;93:1227–32.
Kyaw MH, et al. Evaluation of severe infection and survival after splenectomy. Am J
Med 2006; 119: 276 e1-7.
Madenci AL, et al. Incidence and risk factors for sepsis after childhood splenectomy. J
Pediatr Surg 2019;54:1445–8.
Marrie TJ, et al. Asplenic patients and invasive pneumococcal disease-how bad is it
these days?. Int J Infect Dis 2016;51:27–30.
Quan H, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10
administrative data. Med Care 2005;43:1130–9.
Rubin LG, Schaffner W. Clinical practice. Care of the asplenic patient. N Engl J Med
2014;371:349–56.
Sinwar PD. Overwhelming post splenectomy infection syndrome-review study. Int J
Surg 2014;12:1314–6.
Spijkerman R, et al. A cohort study to evaluate infection prevention protocol in
pediatric trauma patients with blunt splenic injury in a Dutch level 1 trauma
center. Patient Prefer Adherence 2018;12:1607–17.
Theilacker C, et al. Overwhelming postsplenectomy infection: a prospective
multicenter cohort study. Clin Infect Dis 2016;62:871–8.
William BM, et al. Hyposplenism: a comprehensive review. Part II: clinical
manifestations, diagnosis, and management. Hematology 2007;12:89–98.edicine from ClinicalKey.com by Elsevier on November 18, 2020.
opyright ©2020. Elsevier Inc. All rights reserved.
